Share on LinkedInShare on LinkedIn

ARTICLE · 13 NOVEMBER 2013

Federal Circuit Patent Updates - November 2013

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

Sanofi-Aventis v. Pfizer Inc. (No. 2012-1345, 1/5/13) (Newman, Lourie, Davis [of the E.D. Tex., sitting by designation]) =

United StatesIntellectual Property

Sanofi-Aventis v. Pfizer Inc. (No. 2012-1345, 1/5/13) (Newman, Lourie, Davis [of the E.D. Tex., sitting by designation])

November 5, 2013 6:11 PM

Newman, J. Affirming award of priority in an interference. Priority of conception was proven by the isolation of the clamed polynucleotide even without a completely accurate analysis of the entire nucleotide sequence at the time due to sequencing errors that were later corrected. "We conclude that the Board correctly based conception and reduction to practice on the possession of the isolated DNA segment that was shown to have the desired properties. When the subject matter is a DNA segment, conception requires possession and appreciation of the DNA segment that is claimed." "Discussing the consequences of Pfizer's flawed sequence analysis that was corrected after the Sanofi priority date, the Board stated that "[f]or proteins and polynucleotide species, a sequence is the gold standard for identifying species with

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from